Flagstar Financial, Inc.
Case Overview
29 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 02/18/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Flagstar Financial, Inc. |
Court: | Court: Eastern District of New York |
Case Number: | Case Number: 1:24cv08655 |
Class Period: | Class Period: 12/01/2022 - 12/19/2024 |
Ticker: | Ticker: FLG |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of those who acquired Flagstar Financial Inc., f/k/a New York Community Bancorp, Inc. (“NYCB” or the “Company”) (NYSE:FLG) securities pursuant to offering documents issued in connection with the merger between NYCB and Flagstar Financial, Inc., which was announced in April 2021 and closed on December 1, 2022. Investors have until February 18, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On January 31, 2024, NYCB announced a fourth-quarter net loss of $252 million and a reduction in its quarterly dividend, cutting payouts by 71%, from $0.17 to $0.05 per share. These losses were attributed to challenges in the office property sector, repricing risks in its multifamily loan portfolio, and an increase in high-risk loans. Following this news, NYCB’s stock price plummeted by $12.94, or approximately 38%, from $19.41 on January 30, 2024, to $6.47 on January 31, 2024, marking the largest single-day drop in the company’s history.
Furthermore, on February 5, 2024, Bloomberg revealed that NYCB’s two key executives, Chief Risk Officer Nicholas Munson and the Chief Audit Executive, had been removed in recent months, leaving the bank without leadership in these critical roles. Following this news, the price of NYCB dropped $2.31 per share, or approximately 22%, from $10.50 per share on February 5, 2024, to close at $8.19 on February 6, 2024. Then, on February 29, 2024, the Company disclosed a $2.4 billion goodwill impairment related to older transactions and acknowledged material weaknesses in its internal controls. NYCB admitted to ineffective oversight, insufficient risk assessment processes, and inadequate monitoring of its loan portfolio, which hindered its ability to identify problematic loans and provide accurate financial disclosures. On this news, the price of NYCB shares declined by $0.82 per share, or approximately 26%, from $4.37 per share on February 29, 2024, to close at $3.55 on March 1, 2024. It then dropped by an additional $0.82 per share, or approximately 23%, from $3.55 per share on March 1, 2024, to close at $2.73 on March 4, 2024. By March 6, 2024, trading was halted as shares fell as low as $1.70.
The lawsuit alleges that the offering documents misrepresented NYCB’s financial statements’ compliance with GAAP, accounting for goodwill impairment, and financial health. The offering documents also concealed that the merger had been restructured to bypass FDIC approval after the FDIC informally vetoed the transaction due to these risks. Instead, the documents misleadingly stated there were no significant regulatory concerns, giving investors an overly favorable picture of the merger.
On January 31, 2024, NYCB announced a fourth-quarter net loss of $252 million and a reduction in its quarterly dividend, cutting payouts by 71%, from $0.17 to $0.05 per share. These losses were attributed to challenges in the office property sector, repricing risks in its multifamily loan portfolio, and an increase in high-risk loans. Following this news, NYCB’s stock price plummeted by $12.94, or approximately 38%, from $19.41 on January 30, 2024, to $6.47 on January 31, 2024, marking the largest single-day drop in the company’s history.
Furthermore, on February 5, 2024, Bloomberg revealed that NYCB’s two key executives, Chief Risk Officer Nicholas Munson and the Chief Audit Executive, had been removed in recent months, leaving the bank without leadership in these critical roles. Following this news, the price of NYCB dropped $2.31 per share, or approximately 22%, from $10.50 per share on February 5, 2024, to close at $8.19 on February 6, 2024. Then, on February 29, 2024, the Company disclosed a $2.4 billion goodwill impairment related to older transactions and acknowledged material weaknesses in its internal controls. NYCB admitted to ineffective oversight, insufficient risk assessment processes, and inadequate monitoring of its loan portfolio, which hindered its ability to identify problematic loans and provide accurate financial disclosures. On this news, the price of NYCB shares declined by $0.82 per share, or approximately 26%, from $4.37 per share on February 29, 2024, to close at $3.55 on March 1, 2024. It then dropped by an additional $0.82 per share, or approximately 23%, from $3.55 per share on March 1, 2024, to close at $2.73 on March 4, 2024. By March 6, 2024, trading was halted as shares fell as low as $1.70.
The lawsuit alleges that the offering documents misrepresented NYCB’s financial statements’ compliance with GAAP, accounting for goodwill impairment, and financial health. The offering documents also concealed that the merger had been restructured to bypass FDIC approval after the FDIC informally vetoed the transaction due to these risks. Instead, the documents misleadingly stated there were no significant regulatory concerns, giving investors an overly favorable picture of the merger.